SP-2-225

• UNSPSC Description:

  SP-2-225 is a selective HDAC6 inhibitor. SP-2-225 enhance the production of cancer-associated antigens and macrophage antigen cross-presentation to T cells. SP-2-225 reduces the tumor volume in a syngeneic SM1 melanoma model[1].

• Target Antigen:

  HDAC

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/sp-2-225.html

• Solubility:

  10 mM in DMSO

• Smiles:

  CC1=C(COC2=CC=C(CNCCCCCC(NO)=O)C=C2C)C=CC=C1C3=CC=CC=C3

• Molecular Weight:

  446.58

• References & Citations:

  [1]Scott Grindrod, et al. Abstract PO023: Immune-mediated tumor growth inhibition by selective HDAC6 inhibitor SP-2-225. Cancer Immunol Res (2021) 9 (2_Supplement): PO023.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2364448-93-9